Published on: 19 July 2022
The innovative biopharmaceutical industry, having developed COVID-19 vaccines and treatments at record speed and in historic quantities, proposes to create a collaborative solution for more equitable rollout of vaccines, treatments and diagnostics for future pandemics. In particular, the innovative biopharmaceutical industry is willing to reserve an allocation of real-time production of vaccines, treatments and diagnostics for priority populations in lower income countries and take measures to make them available and affordable. To be successful, we call on other stakeholders to work together with industry to help make this proposal a reality and shape a future where everyone is better protected from the threat of pandemics.
